News

‘Emergency backup system’ replenishes platelets


 

Platelets (blue) in a thrombus

Image by Andre E.X. Brown

Preclinical research appears to explain how the body can quickly replenish platelets that are lost during infection.

Investigators discovered an “emergency backup system” in mice that bypasses the known pathway of hematopoietic stem cell (HSC) differentiation so that platelet numbers can be restored rapidly.

Marieke Essers, PhD, of The German Cancer Research Center (Deutsches Krebsforschungszentrum) in Heidelberg, Germany, and her colleagues described this phenomenon in Cell Stem Cell.

The team discovered a small cell population within the HSC compartment that induces differentiation in megakaryocytes.

These quiescent stem cells—dubbed stem-like megakaryocyte-committed progenitors (SL-MkPs)—do not provide the normal supply of platelets but serve as a backup in case of emergency.

When quiescent, SL-MkPs express few proteins. In the event of an acute infection, SL-MkPs are aroused from their quiescent state by interferon α, express the typical megakaryocyte proteins, and are rapidly differentiated into advanced precursor cells.

This quickly replaces the platelets that were lost as a result of the infection.

This emergency backup system bypasses the lengthy process of normal HSC differentiation, thereby ensuring that any life-threatening loss of platelets is compensated for quickly.

However, the investigators found that repeat infections can result in the reservoir of SL-MkPs being depleted.

Recommended Reading

Warfarin as effective as LMWH to prevent recurrent VTEs in cancer patients
MDedge Hematology and Oncology
Clotting tests fail to predict internal bleeding
MDedge Hematology and Oncology
Product can eliminate inhibitors in hemophilia A
MDedge Hematology and Oncology
Treatments appear comparable for VTE in cancer
MDedge Hematology and Oncology
Toward a single, whole-body scan to detect blood clots
MDedge Hematology and Oncology
PICCs linked to lower- and upper-extremity DVT
MDedge Hematology and Oncology
Study shows rivaroxaban can cross placenta
MDedge Hematology and Oncology
Warfarin associated with real-world benefits in AF
MDedge Hematology and Oncology
FDA expands indication for VWD drug
MDedge Hematology and Oncology
Hemophilia A product performs well in 3 trials
MDedge Hematology and Oncology